Adlai Nortye Ltd.
ANL evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for ANL—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · ANL
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing oncology drug candidates, with a pipeline including AN9025, AN4035, and AN8025, and has not yet obtained regulatory approval for any product.
Key risk: No approved products
BioSniper Score
Based on 4 of 6 signals
Financial data as of Dec 31, 2024.
Tracking 7 clinical trials · 1 catalyst for Adlai Nortye Ltd..
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing oncology drug candidates, with a pipeline including AN9025, AN4035, and AN8025, and has not yet obtained regulatory approval for any product.
- Adlai Nortye has a pipeline of drug candidates including AN9025, AN4035, and AN8025, all in clinical or preclinical stages [sec · filed 2026-08-14].
- As of 2024-12-31, the company reported cash & equivalents of $60.9M, net income of -$51.9M, and shareholders' equity of -$185.4M [sec].
- The company has incurred net losses and expects to continue incurring losses for the foreseeable future, with research and development expenses of $44.9M in 2024 [sec · filed 2025-04-30].
- Adlai Nortye is a foreign private issuer and an emerging growth company, allowing it to take advantage of reduced reporting requirements [sec · filed 2025-04-30].
What works
- The company recently expanded its Scientific Advisory Board with two leading medical oncologists from MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center, which may enhance clinical development expertise [sec · filed 2026-08-14].
- Adlai Nortye has a pipeline with multiple drug candidates (AN9025, AN4035, AN8025) advancing through clinical trials, with initial data expected in 2026 and 2027 [sec · filed 2026-08-14].
- The company leverages in-licensed drug candidates and engages contract research organizations to manage clinical trials, potentially reducing internal development costs [sec · filed 2025-04-30].
What to weigh
- None of Adlai Nortye's drug candidates have been approved for marketing in any jurisdiction, and the company has a limited operating history with significant net losses [sec · filed 2025-04-30].
- The company's business depends substantially on the success of its preclinical and clinical drug candidates, and any failure or delay could materially harm the business [sec · filed 2026-04-10].
- Adlai Nortye may need additional financing to fund its drug development programs, as expenses are expected to increase with advancing clinical trials [sec · filed 2026-04-10].
- The company is a 'controlled company' under Nasdaq rules, which may exempt it from certain corporate governance requirements that protect shareholders [sec · filed 2025-04-30].
From the filings
Quoted directly from source documents.
The company has not yet obtained regulatory approval for any drug candidate.
“None of our drug candidates has been approved for marketing in the U.S., Europe, China, or any other jurisdiction.”
SEC filings · April 10, 2026
The company expects to incur significant expenses as it advances clinical development.
“We expect our expenses to increase in connection with our ongoing activities, particularly as we advance the clinical development of our drug candidates, initiate additional clinical trials of these and other future drug candidates, and seek regulatory approvals for them.”
SEC filings · April 10, 2026
The company has a limited operating history and has incurred net losses.
“We have a limited operating history, have incurred net losses and anticipate that we will continue to incur net losses for the foreseeable future.”
SEC filings · April 30, 2025
The company's business depends on the success of its drug candidates.
“Our business depends substantially on the success of our preclinical and clinical drug candidates. If we are unable to successfully develop drug candidates or experience significant delays in doing so, our business will be materially harmed.”
SEC filings · April 10, 2026
Catalyst timeline
- 2026-09-23 · Phase 1 Start for AN9025 — Initiation of a multi-center, open-label, Phase I study evaluating safety, tolerability, pharmacokinetics, and anti-tumor activity.
Risks & what to watch (4)›
Key risks
- No approved products — None of the company's drug candidates have been approved for marketing in any jurisdiction [sec · filed 2026-04-10].
- History of net losses — The company has incurred net losses and expects to continue for the foreseeable future, with net income of -$51.9M as of 2024-12-31 [sec].
- Need for additional financing — The company may need additional financing to fund drug development programs as expenses increase [sec · filed 2026-04-10].
- Controlled company status — As a controlled company, Adlai Nortye may be exempt from certain corporate governance requirements that protect shareholders [sec · filed 2025-04-30].
What to watch
- Initial Phase Ia clinical data from AN9025 QD arm expected in 1H27 [sec · filed 2026-08-14].
- First patient dosing for AN4035 global Phase I trial expected in 2H26, with initial data in 2H27 [sec · filed 2026-08-14].
- AN8025 Phase I dose escalation completion expected by YE 2026 [sec · filed 2026-08-14].
- The company's ability to secure additional financing to support ongoing R&D activities [sec · filed 2026-04-10].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Adlai Nortye Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Adlai Nortye Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
3.6 months
D/E 1.80
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~24d
0 buys · 1 sell (180d)
Runway
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
21
Total value held
$23.3M
| Holder | Shares | Value |
|---|---|---|
| balyasny asset management l.p. | 877,846 | $6.1M |
| millennium management llc | 681,775 | $4.7M |
| adage capital partners gp, l.l.c. | 538,461 | $3.7M |
| superstring capital management lp | 414,852 | $2.9M |
| affinity asset advisors, llc | 164,748 | $1.1M |
| ubs group ag | 122,261 | $846K |
| ameriprise financial inc | 120,156 | $831K |
| adar1 capital management, llc | 117,909 | $816K |
| tidal investments llc | 66,034 | $457K |
| renaissance technologies llc | 66,000 | $457K |
Showing top 10 of 21 institutional holders of Adlai Nortye Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 1, 2026- % of float
- 4.9%
- Days to cover
- 5.3
- Shares short
- 2,294,430
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
ANL short interestFrequently asked questions
What is the AI investment thesis for Adlai Nortye Ltd.?
Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company focused on developing oncology drug candidates, with a pipeline including AN9025, AN4035, and AN8025, and has not yet obtained regulatory approval for any product.
What is Adlai Nortye Ltd.'s next catalyst?
Adlai Nortye Ltd.'s next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Multi-center, Open-label, Phase I Study Evaluating Safety, Tolerability, Pharmacokinetics and Anti" — expected September 23, 2026.
Who is the CEO of Adlai Nortye Ltd.?
Mr. Yang Lu EMBA is the chief executive officer of Adlai Nortye Ltd. (ANL).
Where is Adlai Nortye Ltd. headquartered?
Adlai Nortye Ltd. (ANL) is headquartered in North Brunswick, NJ, United States.
What therapeutic areas does Adlai Nortye Ltd. focus on?
Adlai Nortye Ltd. develops therapies across Oncology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.